Literature DB >> 20683026

The influence of cyclin D1 A870G polymorphism on colorectal cancer risk and prognosis in a Turkish population.

Ilhan Yaylim-Eraltan1, Soykan Arikan, Yemliha Yildiz, Canan Cacina, H Arzu Ergen, Gulay Tuna, Uzay Görmüs, Umit Zeybek, Turgay Isbir.   

Abstract

BACKGROUND: Cyclin D1, encoded by the gene CCND1, is a regulatory protein in the cell cycle transition from G(1) phase to S phase. A common polymorphism (A870G) at codon 242 affects splicing of the CCND1 transcript and may cause uncontrollable cellular growth. The present study was performed to test the association between A870G polymorphisms in the CCND1 gene and colorectal cancer risk and progression. PATIENTS AND METHODS: The 870 A>G polymorphism in the cyclin D1 gene was genotyped in a Turkish colorectal cancer case-control population including fifty-seven cases (35 male, 22 female; mean age + or - SD: 59.33 + or - 13.7 years) and 117 controls (63 male, 54 female; mean age + or - SD: 54.4 + or - 12.2 years) using polymerase chain reaction-restriction fragment length polymorphism analysis.
RESULTS: Genotype frequencies of our patients and controls both confirmed to the Hardy-Weinberg equilibrium. There was no difference in the distribution of CCND1 genotypes and frequencies of the alleles A (59.6% versus 49.6%) and G (40.4% versus 50.4%) in the colorectal cancer patients and controls, respectively. Women homozygous for the cyclin D1 870 GG genotype showed an increased risk for developing colorectal cancer compared to those with the AG+AA genotypes and this result was statistically significant (OR 5.568, 95% CI 1.270-24.417, p=0.02). On the other hand, the cyclin D1 GA genotype was associated with distant metastasis (p=0.016).
CONCLUSION: Our findings suggest that genetic variants of A870G might be associated with distant metastasis and also gender.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20683026

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

1.  Cyclin D1 G870A polymorphism and colorectal cancer susceptibility: a meta-analysis of 20 populations.

Authors:  Lou-Qian Zhang; Jun Wang; Jun-Qing Shang; Jian-Ling Bai; Fu-Yin Liu; Xin Guan; Jian-Nong Zhou
Journal:  Int J Colorectal Dis       Date:  2011-05-05       Impact factor: 2.571

2.  CCND1 G870A polymorphism contributes to the risk of esophageal cancer: An updated systematic review and cumulative meta-analysis.

Authors:  Li Wen; Yuan-Yuan Hu; Gong-Li Yang; DE-Xi Liu
Journal:  Biomed Rep       Date:  2014-05-21

3.  CCND1 G870A polymorphism and colorectal cancer risk: An updated meta-analysis.

Authors:  Xiao-Ming Xu; Xiao-Bing Ni; Gong-Li Yang; Zhi-Guo Luo; Yu-Ming Niu; Ming Shen
Journal:  Mol Clin Oncol       Date:  2016-04-04

Review 4.  Cyclin D1 G870A polymorphism contributes to colorectal cancer susceptibility: evidence from a systematic review of 22 case-control studies.

Authors:  Yongzhi Yang; Feng Wang; Chenzhang Shi; Yang Zou; Huanlong Qin; Yanlei Ma
Journal:  PLoS One       Date:  2012-05-11       Impact factor: 3.240

5.  Investigation of cyclin D1 rs9344 G>A polymorphism in colorectal cancer: a meta-analysis involving 13,642 subjects.

Authors:  Hao Qiu; Chengguo Cheng; Yafeng Wang; Mingqiang Kang; Weifeng Tang; Shuchen Chen; Haiyong Gu; Chao Liu; Yu Chen
Journal:  Onco Targets Ther       Date:  2016-10-27       Impact factor: 4.147

6.  Juglanin ameliorates UVB‑induced skin carcinogenesis via anti‑inflammatory and proapoptotic effects in vivo and in vitro.

Authors:  Gui-Rong Hou; Kang Zeng; Hai-Mei Lan; Qi Wang
Journal:  Int J Mol Med       Date:  2018-03-29       Impact factor: 4.101

7.  Cyclin D1 G870A polymorphism and risk of nasopharyngeal carcinoma: a meta-analysis.

Authors:  Meng Li; Weijian Dai; Huanqin Zhou
Journal:  ScientificWorldJournal       Date:  2013-10-03

8.  Association between cyclin D1 G870A polymorphism and cervical cancer risk: a cumulative meta-analysis involving 2,864 patients and 3,898 controls.

Authors:  Yuan-Yuan Hu; Rong Zheng; Chong Guo; Yu-Ming Niu
Journal:  Diagn Pathol       Date:  2014-09-10       Impact factor: 2.644

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.